Stocks Favored by Analysts: Antero Resources Corporation (NYSE:AR), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

For the current quarter, analysts are expecting Antero Resources Corporation (NYSE:AR) to report EPS of $0.01. This consensus estimate is provided by Zacks Research. After the period that ended on 2016-12-31, Antero Resources Corporation (NYSE:AR) reported an EPS actual of $0.16. The difference between the actual and estimate resulted in a surprise factor of 23.08%. The company is expected to release their next earnings report on or around 2017-05-08. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.

Shares of Antero Resources Corporation (NYSE:AR) have a current ABR or average broker rating of 1.74. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.

Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Antero Resources Corporation (NYSE:AR) is $31.466. The top analyst target is $41, and the lowest target is $25 on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.

In the most recent session, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares have traded -0.25%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $-7.40 away from the 50-day moving average of $378.79 and $-3.21 away from the 200-day moving average of $374.60. From a different angle, the stock has been recently recorded -18.01% off of the 52-week high of 452.96 and +14.15% removed from the 52-week low of 325.35. 

Currently, Regeneron Pharmaceuticals, Inc. has a price to earnings ratio of 48.24. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of 1.59.

Price Target Update

Analysts polled by Thomson Reuters have set a consensus target price of $416.43 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.

Leave a Comment